The sticking point for Sanofi could be Insmed's sky-high valuation, with the report suggesting the pharma group would have to ...
Alongside the CEO appointment, Gianluca Fuggetta joined as chief financial officer. Prior to joining Sibylla, Fuggetta served ...
Prostate Progress, a UK research programme led by Prostate Cancer Research (PCR) in partnership with the NHS, is expanding ...
Livsayis (cemdisiran) has been approved by the FDA for adults with AChR antibody-positive gMG, the most common form of the ...
Sanofi is already a big player in Gaucher disease, selling the ERT Cerezyme (imiglucerase) for all three types, as well as ...
Donald Trump nominated Overton – a White House aide, physician, and vocal opponent of abortion – in the summer. The following ...
MSD has called a halt to three trials of BTK inhibitor nemtabrutinib – added to its pipeline through its $2.7 billion ...
Helus Pharma has revealed data from a phase 3 trial of HLP003 that showed evidence of efficacy in major depressive disorder ...
The UK government has said it will end the NHS's controversial contract with US tech firm Palantir, but not until 2029 – two ...
The FDA has said it cannot approve Summit Therapeutics and Akeso's PD-1xVEGF inhibitor ivonescimab, delaying a drug that is ...
Diabetes drug development has changed more in the last 10 years than in the previous three decades combined. Indeed, today, ...
MSD joins Johnson & Johnson, Novartis, and Eli Lilly among London-based Isomorphic's publicly announced R&D partners. While ...